---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105039"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:39:24.910737+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q2 revenue $47.4M (+7% YoY); net loss narrows to $17.4M; FY guidance reaffirmed

## Summary
- Revenue $47.4M in Q2 2025, up 7% from $44.5M in Q2 2024.
- Net loss $(17.4)M ($(0.28)/share) vs $(21.2)M ($(0.34)/share) a year ago; 18% improvement.
- Adjusted EBITDA loss improved 58% to $(3.6)M from $(8.7)M in Q2 2024.
- Total liquidity $90.7M as of June 30, 2025 ($69.3M cash plus $21.4M revolver).
- Full market release of Nanoplasty, Percuplasty 3D MIS Osteotomy, and SpeedMTP Fusion Systems.

## SEC filing metadata
- accession: 0000950170-25-105039
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017025105039/0000950170-25-105039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017025105039/tmci-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105039
- JSON: https://secwatch.observer/filing/0000950170-25-105039.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.